ArticleEuropean journal of medical research2025
TRIM2 exacerbates the advancement of idiopathic pulmonary fibrosis by modulating β-catenin and endoplasmic reticulum stress.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe progression of idiopathic pulmonary fibrosis (IPF) is closely associated with endoplasmic reticulum stress (ERS). However, its precise regulatory mechanism has not been fully elucidated. As an E3 ubiquitin ligase, the biological function of TRIM2 in IPF and its regulatory role in ERS remain unexplored.
methodsWe analyzed the transcriptomic data of IPF from the Gene Expression Omnibus (GEO) database and collected clinical lung tissue samples. The expression of TRIM2 was detected using quantitative real-time polymerase chain reaction (qRT-PCR), Western blot, and immunohistochemistry (IHC). An in vitro pulmonary fibrosis model was established by treating A549 cells with 10 ng/mL TGF-β1 for 48 h. Based on this model, short hairpin RNA (shRNA) was used to knock down TRIM2 expression. Cell Counting Kit-8 (CCK-8) and scratch assay were employed to evaluate cell proliferation and migration abilities. Additionally, Western blot was performed to analyze the expression changes of epithelial-mesenchymal transition (EMT) markers (E-cadherin, α-SMA, Collagen I), endoplasmic reticulum stress (ERS)-related proteins (p-IRE1, IRE1, ATF6, GRP78), and β-catenin.
resultsThis study demonstrated that TRIM2 was significantly upregulated in both IPF patients' lung tissues and TGF-β1-induced A549 cells. Functional experiments revealed that TRIM2 knockdown markedly suppressed TGF-β1-induced cell proliferation and migration, while reversing the epithelial-mesenchymal transition process-evidenced by increased E-cadherin and decreased α-SMA and Collagen I expression. Mechanistic investigations showed that TRIM2 knockdown effectively inhibited endoplasmic reticulum stress, as indicated by reduced expression of key ERS markers including p-IRE1, IRE1, ATF6, and GRP78. Notably, the ERS inducer thapsigargin reversed the suppressive effects of TRIM2 knockdown on cell proliferation, migration, EMT, and ERS. Furthermore, we discovered, for the first time, that TRIM2 negatively regulates β-catenin expression, and the β-catenin inhibitor JW55 partially restored the fibrotic phenotypes suppressed by TRIM2 knockdown.
conclusionThis study demonstrates that TRIM2 promotes idiopathic pulmonary fibrosis progression by regulating β-catenin expression and endoplasmic reticulum stress, providing new insights into IPF pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.